Clinical trial · Observational
Biomarkers in Bone Marrow Samples From Pediatric Patients With High-Risk Acute Myeloid Leukemia
Target: Identification for High Risk Childhood AML Based on Genome-Wide Analysis
NCT01076569CI-TRIAL-00022300completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This pilot research trial studies biomarkers in bone marrow samples from pediatric patients with high risk acute myeloid leukemia. Studying samples of bone marrow from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer.
Conditions
Conditions (12)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Childhood Acute Basophilic Leukemia | Childhood Acute Basophilic Leukemia | ONTOLOGY_EXACT | 0.98 |
| Childhood Acute Eosinophilic Leukemia | — | UNRESOLVED | — |
| Childhood Acute Erythroleukemia (M6) | Acute Erythroid Leukemia | ALIAS | 0.85 |
| Childhood Acute Megakaryocytic Leukemia (M7) | Childhood Acute Megakaryoblastic Leukemia | ALIAS | 0.90 |
| Childhood Acute Minimally Differentiated Myeloid Leukemia (M0) | Childhood Acute Myeloid Leukemia with Minimal Differentiation | ALIAS | 0.90 |
| Childhood Acute Monoblastic Leukemia (M5a) | Childhood Acute Monoblastic Leukemia | ONTOLOGY_EXACT | 0.85 |
| Childhood Acute Monocytic Leukemia (M5b) | Childhood Acute Monocytic Leukemia | ONTOLOGY_EXACT | 0.85 |
| Childhood Acute Myeloblastic Leukemia With Maturation (M2) |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| laboratory biomarker analysis | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Ancillary-Correlative (molecular analysis)
- description
- Banked bone marrow samples from diagnosis and remission are used to develop a detailed molecular map of pediatric high-risk acute myeloid leukemia. Analysis includes genome SNP genotyping, expression, and methylation profiling.
- interventionNames
- Other: laboratory biomarker analysis
Primary outcomes (8)
- measure
- Detailed molecular map of pediatric high-risk acute myeloid leukemia
- timeFrame
- Baseline
- measure
- Mutations in identifying novel changes associated with pediatric AML
- timeFrame
- Baseline
- measure
- Expression profile in identifying novel changes associated with pediatric AML
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Maximum age
- 21 Years
Show eligibility criteria text
Inclusion Criteria: * Diagnosis of acute myeloid leukemia * High-risk disease * Treated on COG-AAML03P1 or COG-AAML0531 * Meets the following criteria: * Initial remission with no known adverse risk factors * High quantity and quality of ribonucleic acid (RNA) and deoxyribonucleic acid (DNA) available * Highly enriched specimens with \>= 50% blast available
References
Publications (0)
Data not yet available
No reference posted for this study.